Bulevirtide
- CAS No.
- 2012558-47-1
- Chemical Name:
- Bulevirtide
- Synonyms
- MyrB;Bulevirtide;Propofol Impurity 48;Bulevirtide (Myrcludex B);{Myr}-Gly-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Asp-Phe-Asn-Pro-Asn-Lys-Asp-His-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly-NH2
- CBNumber:
- CB96185223
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| form | Solid |
|---|---|
| color | White to off-white |
| FDA UNII | WKM56H3TLB |
| ATC code | J05AX28 |
Bulevirtide Chemical Properties,Uses,Production
Description
Bulevirtide (BLV), the first-in-class entry inhibitor, is a 47-amino acid synthetic liner lipopeptide derived from the preS1 domain of the HBV large surface that targets the NTCP, the entry receptor for HBV/HDV. By blocking this receptor, new infections are prevented, and infected hepatocytes are replaced by naive cells that will be protected from infection. Consequently, viral spread in the liver is prevented.
Biological Activity
The sequence of Bulevirtide (BLV) is derived from that of preS1 from HBV genotype C (residues Gly2-Gly48) with a shortening of the 11 additional N-terminal amino acids and one amino acid substitution, Gln46Lys. BLV exhibits a remarkably high inhibitory constant (IC50?=?140 pM) against HBV and HDV in primary human hepatocytes and HepaRG cells. BLV has also been demonstrated to inhibit the NTCP-mediated uptake of bile salts but at an IC50 in the nanomolar range[1].
References
[1] Liu, Hongtao et al. “Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.” Nature Communications 22 1 (2024).
Bulevirtide Preparation Products And Raw materials
Raw materials
Preparation Products
Bulevirtide Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 16314854226; +16314854226 | inquiry@bocsci.com | United States | 19654 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 52924 | 58 | |
| Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 | admin@nexconn.com | China | 10406 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10473 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38630 | 58 | |
| Zhejiang Hangyu API Co., Ltd | +8617531972939 | anna@api-made.com | China | 2943 | 58 |
| Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | orders@jknbiochem.com | China | 5221 | 58 |
| Changsha MOL Changes Biotechnology Co., Ltd. | +8619375158599 | info@molchanges.com | China | 5223 | 58 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9804 | 58 |
| ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 | 2853530910@QQ.com | China | 8010 | 62 |
Related articles
- Bulevirtide: Pharmacodynamics, Pharmacokinetics and Adverse Events
- Bulevirtide, effective against HBV and HDV, exhibits manageable adverse events, including increased bile salts. Close monitori....
- Apr 22，2024
- Bulevirtide:Application and safety
- Bulevirtide, a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta vir....
- Mar 29，2023
View Lastest Price from Bulevirtide manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-10-28 | Bulevirtide (Myrcludex B)
2012558-47-1
|
US $315.00-923.00 / mg | 10g | TargetMol Chemicals Inc. |
-
- Bulevirtide (Myrcludex B)
2012558-47-1
- US $315.00-923.00 / mg
- TargetMol Chemicals Inc.